Background-Atrial fibrillation (AF) risk has been associated with leaky ryanodine receptor 2 (RyR2) Ca release channels.
A trial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population. 1 Although the cause of AF is multifactorial, there is increasing evidence that AF is a heritable disorder especially in younger patients without underlying structural heart or systemic diseases (lone AF). 2 Mutations in the cardiac ryanodine receptor 2 (RyR2) Ca release channel or in the major sarcoplasmic reticulum (SR) Ca-binding protein, cardiac calsequestrin (Casq2), have been associated with increased risk of AF. 3 Patients with these mutations usually display episodes of catecholamine-induced polymorphic ventricular tachycardia in response to physical or emotional stress. 4 Experimental work has established that ventricular arrhythmias are caused by premature Ca release from the SR that promotes delayed afterdepolarizations (DADs) and triggered activity. 5 A similar mechanism may promote AF in the atria. Consistent with this hypothesis, recent reports suggest that increased SR Ca leak (eg, attributable to RyR2 mutations 6 or RyR2 phosphorylation by calcium/calmodulindependent protein kinase-II 7 ) is associated with increased risk of AF in vivo. Moreover, atrial myocytes isolated from patients with chronic AF exhibit impaired intracellular Ca handling. In particular, human AF myocytes show an increased incidence of SR spontaneous Ca releases relative to SR Ca content 8 comparable with what has been reported in the Casq2 −/− catecholamine-induced polymorphic ventricular tachycardia mouse model. However, the cause-effect link between the rate of diastolic Ca release in atrial cells and incidence of AF in vivo has not been shown. This may in part be attributable to the difficulty of identifying and localizing subthreshold Ca elevations in intact atria of small animal models. Here, we used voltage and Ca optical mapping in intact hearts and isolated atrial myocytes to test the hypothesis that loss of Casq2 causes spontaneous Ca release in atrial tissue and increases susceptibility to AF in structurally normal atria by promoting DADs and triggered activity. We further hypothesized that Ca-triggered AF can be prevented by a mechanism-based approach of suppressing spontaneous Ca release with the R-enantiomer of propafenone, which is a much more potent RyR2 Ca release channel inhibitor than S-propafenone. 9 
Methods
Detailed methods are provided in the Data Supplement.
Animal Use
All studies were performed according to National Institutes of Health guidelines and were approved by the institutional animal care and use committees at Vanderbilt University.
AF Induction

Casq2
+/+ and Casq2 −/− hearts were harvested and perfused in Langendorff mode as previously described. 10 AF was induced by delivering repeated trains of atrial burst pacing (50 Hz, 2 s). Volume-conducted ECG was recorded continuously: AF was defined as rapid and fragmented atrial electrograms present for ≥150 ms. Incidence and duration of AF episodes were quantified in both Casq2 +/+ and Casq2 −/− hearts.
Optical Mapping
Isolated perfused hearts from Casq2 +/+ and Casq2 −/− mice were stained with either di-4-ANEPPS or Rhod-2 dye. Both voltage and Ca maps were acquired with a RedShirt charge-coupled device camera (14 bit, 80×80 pixels, 1000 fps, CardioCCD-SMQ; RedShirt Imaging), during the postpacing interval. All maps were analyzed by 1 operator in blinded fashion with MATLAB (Mathworks, Natick, MA) using custom algorithms. Voltage maps were used to study atrial activation during both sinus rhythm and AF and to quantify the incidence of DADs in Casq2 +/+ and Casq2 −/− atria. In addition, activation maps of the atria during epicardial pacing at constant cycle lengths were obtained to measure atrial conduction velocity (CV) and action potential duration at 90% of repolarization levels. Incidence of distolic spontaneous Ca elevations (SCaEs) in the atria of perfused hearts was investigated by generating Ca fluorescent maps in the postpacing interval (pacing bursts at 50 Hz, 2 s). The amplitude of every SCaE recorded was quantified as a percentage of the Ca transient amplitude during pacing. Only elevations of ≥10% of the preceding atrial Ca transient during pacing were considered for the analysis.
To test the effect of class I antiarrhythmic drugs on SCaEs and AF, Casq2 −/− isolated perfused hearts stained with Rhod-2 AM underwent the pacing protocol twice: first during vehicle infusion and then in the presence of R-propafenone (3 μmol/L), S-propafenone (3 μmol/L), or lidocaine (20 μmol/L), respectively. The lidocaine concentration was chosen to achieve a similar degree of Na channel block as 3 μmol/L of R-propafenone and S-propafenone as evidenced by a comparable increase in the QRS interval (≈25%). Drugs were continuously infused for 15 minutes before pacing was resumed. AF episodes as well as number and amplitude of SCaEs after R-propafenone, S-propafenone, or lidocaine infusion were quantified and compared with the same parameters obtained with vehicle.
Isolated Myocyte Studies
Atrial myocytes were isolated from Casq2 +/+ and Casq2 −/− atria. First, isolated hearts were perfused for 7 to 8 minutes with tyrode buffer containing collagenase type II (25 mg) and protease (2 mg) to obtain a primary digestion. Then, atria were removed and exposed to a secondary enzyme digestion for an additional 15 to 30 minutes. For permeabilized myocyte studies, cells were placed in laminin-coated chambers, washed with relaxing solution for 30 s, and chemically permeabilized by exposure to internal solution containing saponin (40 μg/mL). After 1 minute, the saponin solution was replaced by internal solution containing Fluo 4 pentapotassium salt (0.02 mmol/L). The permeabilized cells were imaged in the line-scan mode after 10 minutes incubation with either vehicle, S-or R-propafenone (10 μmol/L) and analyzed as described. 11 For intact myocyte studies, cells were loaded with Fura-2 AM, and spontaneous Ca waves and trigger beats were measured as described. 111 AF episodes were recorded in 11 of 12 Casq2 −/− hearts (9.3±2.6 episodes per heart). Approximately 14% of all pacing trains triggered AF. Once induced, AF lasted on average for 21.9±13.1 s ( Figure 1D ).
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Statistical Analysis
Next, we compared electric activation in Casq2 −/− atria during sinus rhythm and AF ( Figure 2 ). During sinus rhythm, atrial activation started from 1 single activation site consistent with the sinoatrial node region near the crista terminalis in the posterior right atrium (Figure 2A ). The activation wavefronts then spread simultaneously in 2 directions: to the right atrial appendage and across the pulmonary vein region of the left atrium toward the left atrial appendage. Atrial activation was completed within 12 ms (Figure 2A ). During AF, atrial activation occurred quasi-simultaneously from multiple independent sites (usually 2 or 3) from both atria ( Figure 2B ), with independent foci observed as close as 1 mm. The ectopic activation was preceded by electric silence. A re-entrant pattern of atrial activation was not observed.
We quantified the ectopic activation sites observed during AF by anatomic region: right atrium, pulmonary vein region, and left atrial appendage ( Figure 2C ). Most of the AF activation sites were found in the pulmonary vein area (48%), especially from the lower portion of the pulmonary vein region. The remaining activation sites were equally distributed among both atrial appendages, with 25% of activation sites in the left atrium and 27% in the right atrium ( Figure 2C ). Interestingly, the sinoatrial node region was spared. Taken together, the spatial and temporal activation pattern and the regional distribution suggest that focal activity (ie, by DADs) 14 was responsible for triggering AF in Casq2 −/− hearts. To test this hypothesis, we examined voltage maps of pacing trains that failed to induce AF for evidence of DADs. Because DADs are best observed in the pause following a pacing train, for this analysis we only examined maps with a postpacing pause of ≥100 ms before atrial or ventricular activation resumed. DADs were observed in 43 of the 95 voltage maps analyzed (45%; Figure 3A) . Consistent with the anatomic sites of atrial activation during AF (Figure 2C ), the majority (50%) of DADs were detected in the pulmonary vein region ( Figure 3B ). Pacing-induced DADs were never observed in Casq2 +/+ hearts (n=4).
Casq2 −/− Atria Display Unchanged Atrial Action Potential and CV
Although no clear re-entrant activation was observed in our optical maps, we next investigated whether changes in atrial action potential or CV might contribute to AF susceptibility in Casq2 −/− mice. Action potentials were measured optically ( Figure 4A ) in the right and left atrial appendage of Casq2 −/− and Casq2 +/+ hearts during atrial pacing at a cycle length of 100 ms. Mean action potential duration was not statistically different ( Figure 4B ). Atrial CV was determined for each heart from right atrial appendage activation maps as illustrated in Figure 4C . Mean maximum CV was not statistically different in the 2 groups ( Figure 4D ).
Spontaneous Ca Release in Isolated Casq2
−/− Atrial Myocytes and Intact Casq2 −/− Atria Altered Ca homeostasis with increased frequency and magnitude of Ca waves and sparks has been proposed as a cellular mechanism that can contribute to AF inducibility and maintenance. Therefore, we quantified Ca sparks and Ca waves in isolated permeabilized atrial cells. Compared with Casq2 +/+ , Casq2 −/− atrial cells displayed a significantly higher rate of spontaneous Ca sparks ( Figure 5A ). Furthermore, the frequency of propagated Ca waves was also significantly increased in Casq2 −/− cells ( Figure 5B ). To investigate Ca handling in intact atria, we obtained Ca maps from Casq2 −/− and Casq2 +/+ intact hearts during the postpacing pause. A 5×5 pixel selection was used to sample different areas of both atria to obtain the corresponding Ca fluorescent trace. SCaEs were present in 60% of pacing trains, with 100% (11/11) Casq2 −/− hearts exhibiting SCaEs ( Figure 5C and 5D ). SCaEs were never observed in Casq2 +/+ hearts. Shape, amplitude, and timing of the SCaEs varied greatly in the different areas of the atria consistent with the local nature of these events. The anatomic origin of the SCaE was defined as the atrial site where the deflection in the Ca fluorescence signal was most prominent. Only SCaEs with ≥10% of the pacing-induced Ca transient amplitude were considered for analysis. SCaEs arose most frequently from the pulmonary vein area (58%) followed by the left atrial appendage (22%) and the right atrium (20%; Figure 5E ). The anatomic distribution of SCaEs matched that of DADs ( Figure 3B ) and focal activation sites during AF ( Figure 2C ). These results suggest that Casq2 −/− atria display increased susceptibility to SCaEs in the pulmonary vein region that can lead to DADs and ectopic triggered activity in the same area.
RyR2 Block by R-Propafenone Suppresses SCaEs in Isolated Atrial Myocytes and Intact Atria and Prevents AF
R-propafenone is a class I antiarrhythmic drug with potent RyR2 blocking properties. 9 Incubating Casq2 −/− permeabilized atrial myocytes with R-propafenone for 10 minutes significantly reduced frequency, amplitude, and propagation speed of Ca waves ( Figure 6A and 6B) . In contrast, S-propafenone, which is a much weaker RyR2 channel inhibitor than R-propafenone, 9 had no significant effect on Ca waves (Figure 6A and 6B) . We next tested R-and S-propafenone in intact atrial myocytes using burst pacing to induce spontaneous Ca waves, DADs, and triggered beats ( Figure 6C ). R-propafenone significantly reduced the incidence of spontaneous Ca waves and completely prevented triggered beats, whereas S-propafenone did not ( Figure 6D ).
Given its efficacy in isolated myocytes, we tested R-propafenone in intact hearts. Atrial pacing induced only 4 SCaEs overall in 3 of 8 Casq2
−/− hearts pretreated with R-propafenone, resulting in a significant reduction in SCaE incidence ( Figure 7A and 7B). The amplitude of the few remaining SCaEs recorded in the presence of R-propafenone was also reduced compared with vehicle ( Figure 7C ). The inhibition of spontaneous Ca waves and triggered beats by R-propafenone but not S-propafenone in Casq2 −/− atrial myocytes ( Figure 6 ) strongly suggested that propafenone's suppression of SCaEs in the intact atria is mainly related to its inhibitory effect on RyR2 rather than Na channel block. To test this hypothesis directly, we used S-propafenone and lidocaine on intact atria. S-propafenone is a much weaker RyR2 inhibitor than R-propafenone 9 but blocks Na channels with equal potency. 15 Lidocaine is a class I antiarrhythmic drug with no RyR2 blocking properties. All 3 drugs were administered at concentrations that produced a 25% wider QRS complex, indicating a comparable degree of Na channel block ( Figure 7D ). In contrast to R-propafenone, S-propafenone, and lidocaine had no effect on frequency or amplitude of SCaEs in intact atria ( Figure 7B and 7C). Furthermore, R-propafenone completely prevented pacing-induced AF ( Figure 7E ), whereas both S-propafenone and lidocaine were ineffective ( Figure 7E ). Collectively, these results suggest that R-propafenone's antiarrhythmic efficacy in the Casq2 −/− AF model is attributable to its suppression of Ca waves and SCaEs by inhibition of RyR2 channels.
Discussion
Major New Findings
Our experiments demonstrate a mechanistic link between enhanced frequency of Ca waves in single atrial myocytes, SCaEs and DADs in intact atria, and AF risk. An increased frequency of Ca waves has been observed in atrial cells from patients with AF as well as from several AF animal models. 6, 8, 16 Ca handling dysfunction may contribute both to the initiation and maintenance of chronic AF in patients. 8 Although it has been speculated that increased frequency of Ca waves in atrial myocytes could be responsible for DADs and triggered AF, it has not been shown that these cellular events observed in isolated myocytes are sufficient to cause any changes in intact atria. Here, we identify and localize pacing-induced SCaEs in the intact atria of Casq2 −/− hearts. These local events likely result from the synchronization of Ca waves in several cells and generate DADs and triggered AF as suggested by the colocalization of SCaEs, DADs, and ectopic activation sites close to the pulmonary vein region. This mechanism is further supported by our finding that R-propafenone, a class I antiarrhythmic drug clinically used for the treatment of AF, not only decreases Ca wave rate in single atrial myocytes through inhibition of RyR2 Ca release channels but also significantly reduces SCaE in intact atria and completely suppresses AF in Casq2 −/− hearts. Importantly, S-propafenone and lidocaine, two Na channel inhibitors with either less or no RyR2 blocking properties, fail to prevent SCaEs and AF in intact Casq2 −/− atria.
Regional SCaEs in Intact Atria Increase the Risk of AF in Casq2 −/− Hearts
Our results show that lack of Casq2 increases susceptibility to AF in mice. Both re-entrant and triggered activation patterns have been previously described during AF in RyR2-linked catecholamine-induced polymorphic ventricular tachycardia models. 7 Our optical mapping of AF events in Casq2 −/− hearts consistently revealed 2 to 3 sites of near-simultaneous activation that then propagated to the surrounding areas. This pattern is most consistent with focal triggered activation. Although our mouse model does not show any sign of macroscopic structural abnormality or fibrosis in atria or ventricles, 5 we cannot completely exclude the possibility that micro-reentrant circuits are responsible for sustaining AF. However, when we measured action potential duration at 90% of repolarization levels and CV, 2 main parameters implicated in the risk of functional re-entry, 17 we found them unchanged compared with Casq2 +/+ controls. Consistent with SCaEs triggering focal activation in Casq2 −/− atria, spontaneous SR Ca releases in the form of both Ca sparks (local Ca releases) and Ca waves (propagated subcellular Ca releases) were significantly more frequent in Casq2 −/− isolated atrial myocytes than in controls. Our results support the hypothesis that when Ca waves occur in a sufficient number of adjacent cells at the same time, the phenomenon can be observed at the tissue level and can cause local DADs and triggered activity, as suggested previously. 18 Moreover, their colocalization on voltage and Ca maps in intact atria suggests a causal link between the regional Ca waves, DADs, and triggered ectopic activity. The finding that R-propafenone not only reduces Ca waves in myocytes and SCaEs in intact atria but also completely prevents AF in Casq2 −/− hearts further supports the hypothesis that AF in Casq2 −/− hearts is generated by Ca-induced focal activity.
Casq2 −/− Mice Represent a Model of AF Triggered by Ca-Mediated Enhanced Automaticity
Increased intracellular spontaneous Ca releases have been observed in atrial myocytes of patients with AF without any known mutations in intracellular Ca handling proteins. 16 However, several other electrophysiological and ultrastructural abnormalities are present in these cells, 19 thus making it challenging to determine whether Ca handling dysfunction is the cause of AF or is secondary to disease progression. 20 The Casq2 −/− AF mouse model reported here can be used to address the role of frequent SCaEs in the pathogenesis of AF in the absence of other confounding intracellular perturbations. In addition, reduction of functional Casq2 has been observed in some chronic acquired heart diseases that are associated with increased risk of AF, such as congestive heart failure. 21, 22 It is possible that acquired Casq2 reduction might promote AF in these patients as a complication of a pre-existing chronic cardiac disease. In this context, acquired Ca handling dysfunction could provide local triggers to initiate paroxysmal re-entrant AF sustained by anatomic substrates. Similarly, leakiness of the SR could contribute to postoperative AF where the β-adrenergic stimulation after surgery may increase SR Ca content and spontaneous Ca releases. One limitation of the current study is that AF was induced acutely in mouse hearts by rapid atrial pacing, which may not be relevant to persistent or chronic forms of AF in humans. However, in the clinical electrophysiology laboratory, atrial pacing is often performed to induce paroxysmal AF in patients. Because >70% of paroxysmal AF is thought to be driven by enhanced spontaneous activity originating in the pulmonary veins, rapid atrial pacing may be most relevant to unmasking increased susceptibility to paroxysmal AF in humans.
RyR2 Block by R-Propafenone Prevents AF in Casq2 −/− Isolated Hearts
Currently, the drug management of AF in clinical practice varies considerably, in part that is attributable to the lack of reliably effective therapies for maintaining sinus rhythm and the toxicities associated with antiarrhythmic drugs. Drug efficacy could be improved by targeting the underlying pathophysiology of AF. 2 For example, increased protein kinase A-mediated phosphorylation of RyR2 23, 24 as well as altered phosphatase and phosphodiesterase-4 activity 25, 26 have all been proposed as mechanisms contributing to Ca-triggered AF. The experimental compound S107, a RyR2 channel modulator, has been successfully used to prevent AF in a variety of RyR2 mutant mouse models. 6 Calcium/calmodulin-dependent protein kinase-II has also been identified as a potential therapeutic target because it seems to contribute to the risk of chronic AF by altering RyR2 permeability to Ca; experimentally, calcium/calmodulin-dependent protein kinase-II inhibition reduces SCaEs in isolated atrial myocytes from patients with chronic AF. 8, 27 However, these compounds are not yet ready for patient treatment and will require further testing and clinical trials. Hence, we tested the R-enantiomer of propafenone (the racemic mixture of propafenone is routinely used in clinical practice) and investigated its mode of action in our model of Ca-triggered AF. We previously reported the efficacy of R-propafenone in suppressing ventricular arrhythmias in catecholamine-induced polymorphic ventricular tachycardia because of its dual action as both Na and RyR2 channel blockers. 9 Our new results reported here show that R-propafenone can also completely prevent AF in Casq2 −/− mice, likely through a significant reduction of diastolic SCaEs in intact atria. Importantly, Na channel block in the absence of RyR2 inhibition, as obtained with S-propafenone or lidocaine, was not sufficient to prevent SCaEs and AF in our model of Ca-triggered AF (Figure 7 ). However, we cannot exclude that block of transient outward K currents 28 or L-type Ca currents 29 by propafenone contributed to suppression of SCaEs and AF in Casq2 knockout mice. Propafenone is clinically used as a racemic mixture of Rand S-enantiomers to treat recurrent symptomatic AF as well as pill-in-the-pocket treatment for patients with sporadic paroxysmal AF. 30 However, ≤20% of patients are not responsive to propafenone. 30 Incomplete efficacy of the drug could be attributable to heterogeneity of the underlying AF pathophysiological mechanisms. We speculate that in patients with atrial remodeling and fixed re-entry circuits, propafenone may not be as effective because in that case propafenone RyR2 blocking properties are not exploited. Another possible explanation for the lack of propafenone efficacy in a subset of patients with AF is the use of racemic propafenone. R-propafenone inhibits the metabolism and elimination of S-propafenone, leading to accumulation of S-propafenone during chronic administration. 15 Because S-propafenone was not effective for preventing Ca-triggered AF (our results) and because leaky RyR2s have been observed in many forms of AF, 16 we speculate that R-propafenone might be a more effective mechanism-based treatment than the propafenone racemate currently used in clinical practice. R-propafenone could be considered for clinical drug development.
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